This segment focuses on the research, development, and commercialization of innovative drugs for neurological disorders, with a primary focus on central nervous system (CNS) conditions. Research and development activities include the discovery of novel drug candidates, preclinical studies, and clinical trials across various phases. Technologies and methodologies employed encompass target-based drug discovery, utilizing advanced techniques to identify and validate potential drug targets. The therapeutic areas covered include epilepsy, excessive daytime sleepiness (EDS) associated with narcolepsy or obstructive sleep apnea, Lennox-Gastaut syndrome, and rare neurological diseases. The patient impact is significant, aiming to improve the quality of life for individuals suffering from these debilitating conditions. Market positioning is strengthened by a focus on unmet medical needs and a commitment to developing first-in-class or best-in-class therapies. Future opportunities include expanding the pipeline with new drug candidates and exploring new indications for existing drugs. Regulatory and clinical aspects are critical, with a focus on obtaining FDA and EMA approvals. Partnerships and collaborations are essential for clinical trial execution and commercialization, including collaborations with research institutions and pharmaceutical companies.

This segment is dedicated to the development of radiopharmaceutical therapies, specifically focusing on oncology. Research and development activities include the exploration of Actinium-225 based therapies and small protein-based radiopharmaceuticals. The company is collaborating with research institutions to advance its oncology research capabilities. The therapeutic area covered is oncology, with the aim of developing targeted therapies for cancer treatment. The patient impact is focused on providing innovative treatment options for cancer patients. Market positioning is enhanced through strategic partnerships and collaborations. Future opportunities include expanding the radiopharmaceutical pipeline and becoming a global radiopharmaceutical therapy player. Regulatory and clinical aspects involve navigating the complex regulatory landscape for radiopharmaceuticals. Partnerships and collaborations are crucial for research, development, and commercialization, including agreements with research institutions and other pharmaceutical companies.